Eli Lilly and Company (NYSE:LLY) Stock Holdings Trimmed by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 1.1% in the 4th quarter, HoldingsChannel reports. The firm owned 7,815 shares of the company’s stock after selling 89 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Eli Lilly and Company were worth $6,033,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Concord Wealth Partners lifted its position in Eli Lilly and Company by 6.8% in the fourth quarter. Concord Wealth Partners now owns 5,413 shares of the company’s stock worth $4,179,000 after purchasing an additional 346 shares during the period. Concord Asset Management LLC VA raised its stake in shares of Eli Lilly and Company by 8.3% in the 4th quarter. Concord Asset Management LLC VA now owns 4,917 shares of the company’s stock worth $3,796,000 after buying an additional 377 shares in the last quarter. Chicago Partners Investment Group LLC raised its stake in shares of Eli Lilly and Company by 2.0% in the 4th quarter. Chicago Partners Investment Group LLC now owns 18,897 shares of the company’s stock worth $14,876,000 after buying an additional 369 shares in the last quarter. Waldron Private Wealth LLC lifted its holdings in shares of Eli Lilly and Company by 0.5% in the fourth quarter. Waldron Private Wealth LLC now owns 14,113 shares of the company’s stock valued at $10,895,000 after buying an additional 74 shares during the period. Finally, Scharf Investments LLC boosted its stake in Eli Lilly and Company by 49.9% during the fourth quarter. Scharf Investments LLC now owns 2,240 shares of the company’s stock valued at $1,729,000 after buying an additional 746 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.

Analyst Ratings Changes

LLY has been the topic of several research reports. Wells Fargo & Company cut their price target on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Wolfe Research started coverage on shares of Eli Lilly and Company in a report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price for the company. Barclays dropped their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Finally, Truist Financial raised their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Five equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $997.22.

Eli Lilly and Company Stock Down 1.4 %

Eli Lilly and Company stock opened at $811.61 on Monday. Eli Lilly and Company has a twelve month low of $637.00 and a twelve month high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The firm has a market cap of $770.48 billion, a PE ratio of 87.74, a P/E/G ratio of 1.71 and a beta of 0.41. The firm’s 50 day moving average price is $783.56 and its two-hundred day moving average price is $844.18.

Eli Lilly and Company announced that its Board of Directors has approved a stock buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.74%. Eli Lilly and Company’s dividend payout ratio is 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.